Analysts Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Target Price at $85.33

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been given an average recommendation of “Moderate Buy” by the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $85.3333.

A number of research analysts recently commented on PBH shares. Oppenheimer lowered their price objective on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Canaccord Genuity Group reduced their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Finally, Sidoti upgraded shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price for the company in a research report on Wednesday, September 24th.

Prestige Consumer Healthcare Trading Down 0.7%

NYSE PBH opened at $65.13 on Tuesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.70. Prestige Consumer Healthcare has a one year low of $57.25 and a one year high of $90.04. The company has a 50-day simple moving average of $61.41 and a 200-day simple moving average of $65.23. The firm has a market capitalization of $3.13 billion, a PE ratio of 16.16, a price-to-earnings-growth ratio of 2.04 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The firm had revenue of $274.11 million for the quarter, compared to analysts’ expectations of $257.14 million. During the same quarter last year, the company posted $1.09 earnings per share. Prestige Consumer Healthcare’s revenue was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock in a transaction on Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the sale, the vice president owned 42,329 shares of the company’s stock, valued at $2,539,740. The trade was a 1.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PBH. UMB Bank n.a. lifted its holdings in Prestige Consumer Healthcare by 81.8% in the second quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after purchasing an additional 144 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of Prestige Consumer Healthcare by 312.5% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after acquiring an additional 250 shares during the period. Maseco LLP bought a new position in shares of Prestige Consumer Healthcare in the second quarter valued at approximately $27,000. First Horizon Corp bought a new position in shares of Prestige Consumer Healthcare in the third quarter valued at approximately $32,000. Finally, Barrow Hanley Mewhinney & Strauss LLC increased its stake in shares of Prestige Consumer Healthcare by 106.8% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after acquiring an additional 283 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).